Collegium Pharmaceutical, Inc. · NASDAQ:COLL
Collegium Pharmaceutical — Merger or Acquisition (March 2026)
15 slides from Collegium Pharmaceutical's merger presentation, Mar 19, 2026
Slide 1: Collegium to Acquire AZSTARYS from Corium Therapeutics
Collegium to Acquire AZSTARYS ® from Corium Therapeutics March 19, 2026 | Nasdaq: COLL Healthier people. Stronger communities.
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipat
Slide 3: Strategic Context and Transaction Overview
Strategic Context and Transaction Overview Vikram Karnani President & Chief Executive Officer
Slide 4: Collegium's Path to Building a Leading, Diversified Biopharmaceutical Company
4 Collegium’s Path to Building a Leading, Diversified Biopharmaceutical Company TIME FURTHER EXPANSION Product diversification and capital deployment NEUROPSYCHIATRY & PEDIATRICS PAIN PORTFOLIO FUTURE Guiding Framework for Near - term BD Efforts TARGET THERAPEUTIC AREAS • Neuropsychiatry and pediatr
Slide 5: A Compelling Acquisition that Accelerates Collegium's Growth Strategy
A Compelling Acquisition that Accelerates Collegium’s Growth Strategy • Expands Collegium’s position in ADHD • Leverages existing ADHD sales & marketing infrastructure and expertise • Increases scale, strengthens operating leverage, and expands margins • Immediately accretive to adjusted EBITDA • Fu
Slide 6: Transaction and Financial Details
TIMING: Expected to close in Q2 2026 Purchase Price Transaction and Financial Details 1 • $650 million in cash • Up to $135 million in potential milestone payments based on future commercial and regulatory milestones 6 Funding for Acquisition • $350 million cash on hand • $300 million delayed draw t
Slide 7: Provides Attractive Commercial and Financial Benefits to Collegium
Commercial Impact Financial Impact Provides Attractive Commercial and Financial Benefits to Collegium 7 Accelerate AZSTARYS growth trajectory • Benefit of Collegium’s ADHD commercial infrastructure and expertise • Ability to invest behind the brand Leverage existing Collegium infrastructure • Shared
Slide 8: The Future of Collegium's ADHD Portfolio
The Future of Collegium’s ADHD Portfolio Scott Dreyer Executive Vice President & Chief Commercial Officer
Slide 9: Overview of U.S. ADHD Market and Key Commercial Dynamics
9 Total ADHD Market annual prescriptions Stimulants annual prescriptions annual prescriptions 1. Large and growing market 8% CAGR from 2020 - 2025 2. High patient unmet need Patients on average try ~3 different ADHD medicines before finding right treatment 2 3. Stimulants remain the preferred treatm
Slide 10: Two ADHD Medicines with Strong Support from HCPs that Address Patient Unmet Need
Two ADHD Medicines with Strong Support from HCPs that Address Patient Unmet Need 1 10 Established positions in current ADHD market Viewed as highly favorable amongst HCPs Of HCPs surveyed, 70% indicated intent to increase prescribing of JORNAY PM; 53% plan to increase prescribing of AZSTARYS ≥70% of
Slide 11: Highly Complementary Combination to Increase Collegium's Impact within the ADHD Community
11 Highly Complementary Combination to Increase Collegium’s Impact within the ADHD Community and Better Serve Patients • Dual immediate and long - acting profile • First and only ADHD treatment with both fast and long - acting medicines in one capsule • Dual delayed and extended - release technology
Slide 12: Closing Remarks
Closing Remarks Vikram Karnani President & Chief Executive Officer
Slide 13: Business Development Objectives
Business Development Objectives Acquisition Aligns with Business Development Strategy and Accelerates Revenue and AEBITDA 1 Growth for Collegium 13 Adds to Collegium’s leadership position in ADHD and leverages existing infrastructure x Differentiated, commercial - stage assets to diversify portfolio
Slide 14: Creating Value for Shareholders
Creating Value for Shareholders 14 14 2026 STRATEGIC PRIORITIES VALUE CREATION 1. Drive significant growth for JORNAY PM 2. Maximize the durability of the Pain Portfolio 3. Strategically deploy capital • Business Development • Debt repayment • Share repurchases Grow Revenues Extend longevity Increas
Slide 15: Questions
Questions a SC allee talc
Collegium Pharmaceutical — Merger or Acquisition (March 2026) on 6ix